Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (59)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bien, C. G.
Right arrow Articles by Elger, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bien, C. G.
Right arrow Articles by Elger, C. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 8, 1751-1759, August 2002
© 2002 Guarantors of Brain

The natural history of Rasmussen’s encephalitis

Christian G. Bien1, Guido Widman1, Horst Urbach2, Robert Sassen1, Stefan Kuczaty1, Otmar D. Wiestler3, Johannes Schramm4 and Christian E. Elger1

Departments of 1 Epileptology, 2 Radiology/Neuroradiology, 3 Neuropathology and 4 Neurosurgery, University of Bonn, Bonn, Germany

Correspondence to: C. G. Bien, Department of Epileptology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany E-mail: christian.bien{at}ukb.uni-bonn.de

Rasmussen’s encephalitis (RE) is a chronic inflammatory disease of unknown origin, usually affecting one brain hemisphere. In the present study, a comprehensive assessment of the natural history of the disorder is presented. Seizure frequency, degree of hemiparesis and degree of cerebral hemiatrophy in 13 patients with histopathologically proven RE are analysed over the time course prior to resective epilepsy surgery or introduction of long-term immunosuppressive pharmacotherapy. For the assessment of the degree of cerebral hemiatrophy, on defined slices comprising the Sylvian fissure of hard copies of serial MRI investigations, the hemispheric ratio (HR) was determined. The data show an initial prodromal phase with an intermediate frequency of focal onset seizures and mostly no hemiparesis. The occurrence of this stage was mainly observed in the adolescent and adult patients. All patients went through an acute phase with a median duration of 8 months. During this stage, there were frequent simple partial motor seizures, development of hemiparesis and volume loss of the affected hemisphere. After this, the patients passed into a residual stage with a marked decrease in seizure frequency. Twelve months after the onset of the acute stage, the average HR was 0.72. These data allow an estimation of the prognosis of newly affected patients, and demonstrate that most of the brain damage in RE occurs during the first 8–12 months. These findings should be taken into consideration when future therapeutic approaches to RE are evaluated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BMJ Case ReportsHome page
C M Quesada, H Urbach, C E Elger, and C G Bien
Rasmussen encephalitis with ipsilateral brain stem involvement in an adult patient
BMJ Case Reports, January 22, 2009; 2009(jan21_1): bcr0820080648 - bcr0820080648.
[Abstract] [Full Text]


Home page
J Child NeurolHome page
M. Matsuo, Y. Takahashi, K. Taniguchi, K. Sasaki, and Y. Hamasaki
Chronic Myoclonia of Subcortical Origin With Antiglutamate Receptor Antibodies
J Child Neurol, December 1, 2007; 22(12): 1393 - 1396.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
C M Quesada, H Urbach, C E Elger, and C G Bien
Rasmussen encephalitis with ipsilateral brain stem involvement in an adult patient
J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 200 - 201.
[Full Text] [PDF]


Home page
J Child NeurolHome page
B. Tziperman, B.-Z. Garty, N. Schoenfeld, V. Hoffer, N. Watemberg, D. Lev, Y. Ganor, M. Levite, and T. Lerman-Sagie
Acute Intermittent Porphyria, Rasmussen Encephalitis, or Both?
J Child Neurol, January 1, 2007; 22(1): 99 - 105.
[Abstract] [PDF]


Home page
PNHome page
J. Gawler
A "glioma" that was cured
Practical Neurology, April 1, 2006; 6(2): 117 - 121.
[Full Text] [PDF]


Home page
NeurologyHome page
R. Watson, J.E.C. Jepson, I. Bermudez, S. Alexander, Y. Hart, K. McKnight, A. Roubertie, F. Fecto, J. Valmier, D. B. Sattelle, et al.
{alpha}7-Acetylcholine receptor antibodies in two patients with Rasmussen encephalitis
Neurology, December 13, 2005; 65(11): 1802 - 1804.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. Larionov, R. Konig, H. Urbach, R. Sassen, C. E. Elger, and C. G. Bien
MRI brain volumetry in Rasmussen encephalitis: The fate of affected and "unaffected" hemispheres
Neurology, March 8, 2005; 64(5): 885 - 887.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. G. Bien, T. Granata, C. Antozzi, J. H. Cross, O. Dulac, M. Kurthen, H. Lassmann, R. Mantegazza, J.-G. Villemure, R. Spreafico, et al.
Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement
Brain, March 1, 2005; 128(3): 454 - 471.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. Watson, Y. Jiang, I. Bermudez, L. Houlihan, L. Clover, K. McKnight, J. H. Cross, I. K. Hart, A. Roubertie, J. Valmier, et al.
Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis
Neurology, July 13, 2004; 63(1): 43 - 50.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. G. Bien, U. Gleissner, R. Sassen, G. Widman, H. Urbach, and C. E. Elger
An open study of tacrolimus therapy in Rasmussen encephalitis
Neurology, June 8, 2004; 62(11): 2106 - 2109.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
H. Urbach, J. Hattingen, J. von Oertzen, C. Luyken, H. Clusmann, T. Kral, M. Kurthen, J. Schramm, I. Blumcke, and H. H. Schild
MR Imaging in the Presurgical Workup of Patients with Drug-Resistant Epilepsy
AJNR Am. J. Neuroradiol., June 1, 2004; 25(6): 919 - 926.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
I. Korn-Lubetzki, C. G. Bien, J. Bauer, M. Gomori, H. Wiendl, L. Trajo, H. Ovadia, B. Wilken, V. H. Hans, C. E. Elger, et al.
Rasmussen encephalitis with active inflammation and delayed seizures onset
Neurology, March 23, 2004; 62(6): 984 - 986.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
T. Granata, L. Fusco, G. Gobbi, E. Freri, F. Ragona, G. Broggi, R. Mantegazza, L. Giordano, F. Villani, G. Capovilla, et al.
Experience with immunomodulatory treatments in Rasmussen's encephalitis
Neurology, December 23, 2003; 61(12): 1807 - 1810.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
Y. Takahashi, H. Mori, M. Mishina, M. Watanabe, T. Fujiwara, J. Shimomura, H. Aiba, T. Miyajima, Y. Saito, A. Nezu, et al.
Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua
Neurology, October 14, 2003; 61(7): 891 - 896.
[Abstract] [Full Text] [PDF]


Home page
JWatch NeurologyHome page
Rasmussen's Encephalitis: Natural History Described
Journal Watch Neurology, October 11, 2002; 2002(1011): 4 - 4.
[Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.